nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2D6—breast cancer	0.104	0.389	CbGaD
Citalopram—CYP3A4—breast cancer	0.0896	0.333	CbGaD
Citalopram—ABCB1—breast cancer	0.0746	0.278	CbGaD
Citalopram—CYP2B6—Thiotepa—breast cancer	0.0298	0.0702	CbGbCtD
Citalopram—CYP1A2—Anastrozole—breast cancer	0.0231	0.0543	CbGbCtD
Citalopram—CYP1A2—Toremifene—breast cancer	0.0211	0.0497	CbGbCtD
Citalopram—CYP2B6—Raloxifene—breast cancer	0.0199	0.0468	CbGbCtD
Citalopram—ABCB1—Toremifene—breast cancer	0.0185	0.0434	CbGbCtD
Citalopram—CYP2C19—Lapatinib—breast cancer	0.0167	0.0393	CbGbCtD
Citalopram—CYP3A4—Exemestane—breast cancer	0.016	0.0375	CbGbCtD
Citalopram—CYP2D6—Idarubicin—breast cancer	0.0144	0.0339	CbGbCtD
Citalopram—CYP3A4—Letrozole—breast cancer	0.0136	0.0319	CbGbCtD
Citalopram—ABCB1—Lapatinib—breast cancer	0.0135	0.0317	CbGbCtD
Citalopram—CYP2E1—Tamoxifen—breast cancer	0.0133	0.0314	CbGbCtD
Citalopram—CYP2B6—Tamoxifen—breast cancer	0.0131	0.0309	CbGbCtD
Citalopram—CYP2E1—Mitoxantrone—breast cancer	0.013	0.0306	CbGbCtD
Citalopram—CYP3A4—Anastrozole—breast cancer	0.0121	0.0284	CbGbCtD
Citalopram—CYP3A4—Toremifene—breast cancer	0.0111	0.026	CbGbCtD
Citalopram—CYP3A4—Fulvestrant—breast cancer	0.0103	0.0242	CbGbCtD
Citalopram—CYP2B6—Irinotecan—breast cancer	0.0101	0.0238	CbGbCtD
Citalopram—CYP3A4—Thiotepa—breast cancer	0.00916	0.0216	CbGbCtD
Citalopram—CYP3A4—Ixabepilone—breast cancer	0.00838	0.0197	CbGbCtD
Citalopram—CYP2C19—Tamoxifen—breast cancer	0.00836	0.0197	CbGbCtD
Citalopram—CYP3A4—Lapatinib—breast cancer	0.00807	0.019	CbGbCtD
Citalopram—CYP1A2—Tamoxifen—breast cancer	0.00771	0.0181	CbGbCtD
Citalopram—ABCB1—Vinorelbine—breast cancer	0.00747	0.0176	CbGbCtD
Citalopram—CYP2D6—Vinorelbine—breast cancer	0.00704	0.0166	CbGbCtD
Citalopram—ABCB1—Tamoxifen—breast cancer	0.00674	0.0159	CbGbCtD
Citalopram—ABCB1—Mitoxantrone—breast cancer	0.00657	0.0155	CbGbCtD
Citalopram—CYP2D6—Tamoxifen—breast cancer	0.00635	0.0149	CbGbCtD
Citalopram—CYP3A4—Raloxifene—breast cancer	0.00611	0.0144	CbGbCtD
Citalopram—ABCB1—Gemcitabine—breast cancer	0.00581	0.0137	CbGbCtD
Citalopram—CYP1A2—Fluorouracil—breast cancer	0.00568	0.0134	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—breast cancer	0.00552	0.013	CbGbCtD
Citalopram—ABCB1—Paclitaxel—breast cancer	0.00525	0.0123	CbGbCtD
Citalopram—ABCB1—Irinotecan—breast cancer	0.00518	0.0122	CbGbCtD
Citalopram—ABCB1—Vinblastine—breast cancer	0.0046	0.0108	CbGbCtD
Citalopram—CYP3A4—Vinorelbine—breast cancer	0.00447	0.0105	CbGbCtD
Citalopram—CYP2D6—Vinblastine—breast cancer	0.00434	0.0102	CbGbCtD
Citalopram—CYP3A4—Tamoxifen—breast cancer	0.00404	0.0095	CbGbCtD
Citalopram—CYP3A4—Mitoxantrone—breast cancer	0.00394	0.00927	CbGbCtD
Citalopram—ABCB1—Docetaxel—breast cancer	0.00379	0.00893	CbGbCtD
Citalopram—CYP3A4—Paclitaxel—breast cancer	0.00314	0.0074	CbGbCtD
Citalopram—CYP3A4—Irinotecan—breast cancer	0.0031	0.0073	CbGbCtD
Citalopram—ABCB1—Doxorubicin—breast cancer	0.00283	0.00665	CbGbCtD
Citalopram—CYP3A4—Vinblastine—breast cancer	0.00276	0.00649	CbGbCtD
Citalopram—ABCB1—Methotrexate—breast cancer	0.00274	0.00644	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—breast cancer	0.00266	0.00627	CbGbCtD
Citalopram—CYP3A4—Docetaxel—breast cancer	0.00227	0.00535	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—breast cancer	0.00169	0.00399	CbGbCtD
Citalopram—Escitalopram—CYP2D6—breast cancer	0.000978	0.538	CrCbGaD
Citalopram—Escitalopram—CYP3A4—breast cancer	0.000839	0.462	CrCbGaD
Citalopram—Urethral disorder—Doxorubicin—breast cancer	1.46e-05	6.61e-05	CcSEcCtD
Citalopram—Nausea—Mitoxantrone—breast cancer	1.45e-05	6.6e-05	CcSEcCtD
Citalopram—Nausea—Irinotecan—breast cancer	1.45e-05	6.6e-05	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—breast cancer	1.45e-05	6.58e-05	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—breast cancer	1.45e-05	6.57e-05	CcSEcCtD
Citalopram—Pain—Docetaxel—breast cancer	1.45e-05	6.57e-05	CcSEcCtD
Citalopram—Constipation—Docetaxel—breast cancer	1.45e-05	6.57e-05	CcSEcCtD
Citalopram—Back pain—Methotrexate—breast cancer	1.44e-05	6.56e-05	CcSEcCtD
Citalopram—Dyspepsia—Capecitabine—breast cancer	1.44e-05	6.54e-05	CcSEcCtD
Citalopram—Chills—Epirubicin—breast cancer	1.44e-05	6.54e-05	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—breast cancer	1.43e-05	6.51e-05	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—breast cancer	1.43e-05	6.5e-05	CcSEcCtD
Citalopram—Asthenia—Paclitaxel—breast cancer	1.43e-05	6.5e-05	CcSEcCtD
Citalopram—Decreased appetite—Capecitabine—breast cancer	1.42e-05	6.46e-05	CcSEcCtD
Citalopram—Alopecia—Epirubicin—breast cancer	1.42e-05	6.44e-05	CcSEcCtD
Citalopram—Nausea—Gemcitabine—breast cancer	1.42e-05	6.43e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Capecitabine—breast cancer	1.41e-05	6.42e-05	CcSEcCtD
Citalopram—Fatigue—Capecitabine—breast cancer	1.41e-05	6.41e-05	CcSEcCtD
Citalopram—Pruritus—Paclitaxel—breast cancer	1.41e-05	6.41e-05	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—breast cancer	1.41e-05	6.39e-05	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—breast cancer	1.41e-05	6.39e-05	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—breast cancer	1.4e-05	6.38e-05	CcSEcCtD
Citalopram—Constipation—Capecitabine—breast cancer	1.4e-05	6.36e-05	CcSEcCtD
Citalopram—Pain—Capecitabine—breast cancer	1.4e-05	6.36e-05	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—breast cancer	1.4e-05	6.35e-05	CcSEcCtD
Citalopram—Erythema—Epirubicin—breast cancer	1.4e-05	6.35e-05	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—breast cancer	1.39e-05	6.33e-05	CcSEcCtD
Citalopram—Nausea—Fluorouracil—breast cancer	1.39e-05	6.32e-05	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—breast cancer	1.39e-05	6.3e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—breast cancer	1.39e-05	6.29e-05	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—breast cancer	1.39e-05	6.29e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—breast cancer	1.38e-05	6.28e-05	CcSEcCtD
Citalopram—Anaemia—Methotrexate—breast cancer	1.38e-05	6.27e-05	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—breast cancer	1.38e-05	6.26e-05	CcSEcCtD
Citalopram—Flushing—Doxorubicin—breast cancer	1.38e-05	6.26e-05	CcSEcCtD
Citalopram—Flatulence—Epirubicin—breast cancer	1.38e-05	6.25e-05	CcSEcCtD
Citalopram—Tension—Epirubicin—breast cancer	1.37e-05	6.23e-05	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—breast cancer	1.37e-05	6.21e-05	CcSEcCtD
Citalopram—Diarrhoea—Paclitaxel—breast cancer	1.37e-05	6.2e-05	CcSEcCtD
Citalopram—Nervousness—Epirubicin—breast cancer	1.36e-05	6.16e-05	CcSEcCtD
Citalopram—Back pain—Epirubicin—breast cancer	1.35e-05	6.14e-05	CcSEcCtD
Citalopram—Feeling abnormal—Capecitabine—breast cancer	1.35e-05	6.13e-05	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—breast cancer	1.35e-05	6.12e-05	CcSEcCtD
Citalopram—Malaise—Methotrexate—breast cancer	1.35e-05	6.12e-05	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—breast cancer	1.34e-05	6.1e-05	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—breast cancer	1.34e-05	6.09e-05	CcSEcCtD
Citalopram—Vertigo—Methotrexate—breast cancer	1.34e-05	6.09e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Capecitabine—breast cancer	1.34e-05	6.08e-05	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—breast cancer	1.34e-05	6.08e-05	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—breast cancer	1.34e-05	6.07e-05	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—breast cancer	1.34e-05	6.07e-05	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—breast cancer	1.34e-05	6.07e-05	CcSEcCtD
Citalopram—Chills—Doxorubicin—breast cancer	1.33e-05	6.05e-05	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—breast cancer	1.33e-05	6.03e-05	CcSEcCtD
Citalopram—Dizziness—Paclitaxel—breast cancer	1.32e-05	5.99e-05	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—breast cancer	1.32e-05	5.98e-05	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—breast cancer	1.31e-05	5.96e-05	CcSEcCtD
Citalopram—Cough—Methotrexate—breast cancer	1.3e-05	5.92e-05	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—breast cancer	1.3e-05	5.91e-05	CcSEcCtD
Citalopram—Urticaria—Capecitabine—breast cancer	1.3e-05	5.91e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—breast cancer	1.3e-05	5.89e-05	CcSEcCtD
Citalopram—Body temperature increased—Capecitabine—breast cancer	1.29e-05	5.88e-05	CcSEcCtD
Citalopram—Abdominal pain—Capecitabine—breast cancer	1.29e-05	5.88e-05	CcSEcCtD
Citalopram—Convulsion—Methotrexate—breast cancer	1.29e-05	5.88e-05	CcSEcCtD
Citalopram—Erythema—Doxorubicin—breast cancer	1.29e-05	5.87e-05	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—breast cancer	1.29e-05	5.87e-05	CcSEcCtD
Citalopram—Anaemia—Epirubicin—breast cancer	1.29e-05	5.87e-05	CcSEcCtD
Citalopram—Agitation—Epirubicin—breast cancer	1.28e-05	5.83e-05	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—breast cancer	1.27e-05	5.79e-05	CcSEcCtD
Citalopram—Myalgia—Methotrexate—breast cancer	1.27e-05	5.77e-05	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—breast cancer	1.27e-05	5.77e-05	CcSEcCtD
Citalopram—Chest pain—Methotrexate—breast cancer	1.27e-05	5.77e-05	CcSEcCtD
Citalopram—Tension—Doxorubicin—breast cancer	1.27e-05	5.76e-05	CcSEcCtD
Citalopram—Vomiting—Paclitaxel—breast cancer	1.27e-05	5.76e-05	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—breast cancer	1.27e-05	5.75e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.26e-05	5.73e-05	CcSEcCtD
Citalopram—Malaise—Epirubicin—breast cancer	1.26e-05	5.72e-05	CcSEcCtD
Citalopram—Rash—Paclitaxel—breast cancer	1.26e-05	5.71e-05	CcSEcCtD
Citalopram—Dermatitis—Paclitaxel—breast cancer	1.26e-05	5.71e-05	CcSEcCtD
Citalopram—Discomfort—Methotrexate—breast cancer	1.26e-05	5.7e-05	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—breast cancer	1.26e-05	5.7e-05	CcSEcCtD
Citalopram—Vertigo—Epirubicin—breast cancer	1.26e-05	5.7e-05	CcSEcCtD
Citalopram—Syncope—Epirubicin—breast cancer	1.25e-05	5.69e-05	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—breast cancer	1.25e-05	5.68e-05	CcSEcCtD
Citalopram—Back pain—Doxorubicin—breast cancer	1.25e-05	5.68e-05	CcSEcCtD
Citalopram—Headache—Paclitaxel—breast cancer	1.25e-05	5.68e-05	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—breast cancer	1.25e-05	5.66e-05	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—breast cancer	1.24e-05	5.65e-05	CcSEcCtD
Citalopram—Palpitations—Epirubicin—breast cancer	1.24e-05	5.61e-05	CcSEcCtD
Citalopram—Confusional state—Methotrexate—breast cancer	1.23e-05	5.58e-05	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—breast cancer	1.23e-05	5.58e-05	CcSEcCtD
Citalopram—Cough—Epirubicin—breast cancer	1.22e-05	5.54e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—breast cancer	1.22e-05	5.53e-05	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—breast cancer	1.22e-05	5.53e-05	CcSEcCtD
Citalopram—Asthenia—Docetaxel—breast cancer	1.21e-05	5.51e-05	CcSEcCtD
Citalopram—Convulsion—Epirubicin—breast cancer	1.21e-05	5.5e-05	CcSEcCtD
Citalopram—Infection—Methotrexate—breast cancer	1.21e-05	5.5e-05	CcSEcCtD
Citalopram—Hypertension—Epirubicin—breast cancer	1.21e-05	5.48e-05	CcSEcCtD
Citalopram—Hypersensitivity—Capecitabine—breast cancer	1.21e-05	5.48e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—breast cancer	1.2e-05	5.45e-05	CcSEcCtD
Citalopram—Pruritus—Docetaxel—breast cancer	1.2e-05	5.43e-05	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—breast cancer	1.2e-05	5.43e-05	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—breast cancer	1.2e-05	5.43e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—breast cancer	1.19e-05	5.42e-05	CcSEcCtD
Citalopram—Chest pain—Epirubicin—breast cancer	1.19e-05	5.4e-05	CcSEcCtD
Citalopram—Myalgia—Epirubicin—breast cancer	1.19e-05	5.4e-05	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—breast cancer	1.19e-05	5.4e-05	CcSEcCtD
Citalopram—Agitation—Doxorubicin—breast cancer	1.19e-05	5.4e-05	CcSEcCtD
Citalopram—Anxiety—Epirubicin—breast cancer	1.19e-05	5.38e-05	CcSEcCtD
Citalopram—Nausea—Paclitaxel—breast cancer	1.19e-05	5.38e-05	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—breast cancer	1.18e-05	5.38e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.18e-05	5.37e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—breast cancer	1.18e-05	5.35e-05	CcSEcCtD
Citalopram—Discomfort—Epirubicin—breast cancer	1.18e-05	5.34e-05	CcSEcCtD
Citalopram—Asthenia—Capecitabine—breast cancer	1.17e-05	5.33e-05	CcSEcCtD
Citalopram—Malaise—Doxorubicin—breast cancer	1.17e-05	5.3e-05	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—breast cancer	1.16e-05	5.28e-05	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—breast cancer	1.16e-05	5.28e-05	CcSEcCtD
Citalopram—Anorexia—Methotrexate—breast cancer	1.16e-05	5.28e-05	CcSEcCtD
Citalopram—Syncope—Doxorubicin—breast cancer	1.16e-05	5.27e-05	CcSEcCtD
Citalopram—Pruritus—Capecitabine—breast cancer	1.16e-05	5.26e-05	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—breast cancer	1.16e-05	5.26e-05	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—breast cancer	1.16e-05	5.25e-05	CcSEcCtD
Citalopram—Confusional state—Epirubicin—breast cancer	1.15e-05	5.22e-05	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—breast cancer	1.14e-05	5.19e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—breast cancer	1.14e-05	5.18e-05	CcSEcCtD
Citalopram—Oedema—Epirubicin—breast cancer	1.14e-05	5.18e-05	CcSEcCtD
Citalopram—Hypotension—Methotrexate—breast cancer	1.14e-05	5.17e-05	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—breast cancer	1.14e-05	5.16e-05	CcSEcCtD
Citalopram—Infection—Epirubicin—breast cancer	1.13e-05	5.15e-05	CcSEcCtD
Citalopram—Cough—Doxorubicin—breast cancer	1.13e-05	5.12e-05	CcSEcCtD
Citalopram—Shock—Epirubicin—breast cancer	1.12e-05	5.1e-05	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—breast cancer	1.12e-05	5.09e-05	CcSEcCtD
Citalopram—Diarrhoea—Capecitabine—breast cancer	1.12e-05	5.09e-05	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—breast cancer	1.12e-05	5.08e-05	CcSEcCtD
Citalopram—Dizziness—Docetaxel—breast cancer	1.12e-05	5.08e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—breast cancer	1.12e-05	5.07e-05	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—breast cancer	1.12e-05	5.07e-05	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—breast cancer	1.11e-05	5.05e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—breast cancer	1.11e-05	5.04e-05	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—breast cancer	1.11e-05	5.03e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—breast cancer	1.1e-05	5.01e-05	CcSEcCtD
Citalopram—Insomnia—Methotrexate—breast cancer	1.1e-05	5.01e-05	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—breast cancer	1.1e-05	5e-05	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—breast cancer	1.1e-05	5e-05	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—breast cancer	1.1e-05	5e-05	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—breast cancer	1.1e-05	4.98e-05	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—breast cancer	1.09e-05	4.97e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.09e-05	4.96e-05	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—breast cancer	1.09e-05	4.94e-05	CcSEcCtD
Citalopram—Anorexia—Epirubicin—breast cancer	1.09e-05	4.94e-05	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—breast cancer	1.09e-05	4.93e-05	CcSEcCtD
Citalopram—Somnolence—Methotrexate—breast cancer	1.08e-05	4.92e-05	CcSEcCtD
Citalopram—Dizziness—Capecitabine—breast cancer	1.08e-05	4.92e-05	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—breast cancer	1.08e-05	4.89e-05	CcSEcCtD
Citalopram—Vomiting—Docetaxel—breast cancer	1.08e-05	4.88e-05	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—breast cancer	1.07e-05	4.87e-05	CcSEcCtD
Citalopram—Rash—Docetaxel—breast cancer	1.07e-05	4.84e-05	CcSEcCtD
Citalopram—Hypotension—Epirubicin—breast cancer	1.07e-05	4.84e-05	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—breast cancer	1.07e-05	4.84e-05	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—breast cancer	1.06e-05	4.83e-05	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—breast cancer	1.06e-05	4.81e-05	CcSEcCtD
Citalopram—Headache—Docetaxel—breast cancer	1.06e-05	4.81e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—breast cancer	1.06e-05	4.79e-05	CcSEcCtD
Citalopram—Oedema—Doxorubicin—breast cancer	1.06e-05	4.79e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—breast cancer	1.05e-05	4.78e-05	CcSEcCtD
Citalopram—Fatigue—Methotrexate—breast cancer	1.05e-05	4.77e-05	CcSEcCtD
Citalopram—Infection—Doxorubicin—breast cancer	1.05e-05	4.76e-05	CcSEcCtD
Citalopram—Pain—Methotrexate—breast cancer	1.04e-05	4.73e-05	CcSEcCtD
Citalopram—Vomiting—Capecitabine—breast cancer	1.04e-05	4.73e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—breast cancer	1.04e-05	4.72e-05	CcSEcCtD
Citalopram—Shock—Doxorubicin—breast cancer	1.04e-05	4.71e-05	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—breast cancer	1.04e-05	4.7e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—breast cancer	1.03e-05	4.69e-05	CcSEcCtD
Citalopram—Rash—Capecitabine—breast cancer	1.03e-05	4.69e-05	CcSEcCtD
Citalopram—Insomnia—Epirubicin—breast cancer	1.03e-05	4.68e-05	CcSEcCtD
Citalopram—Dermatitis—Capecitabine—breast cancer	1.03e-05	4.68e-05	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—breast cancer	1.03e-05	4.68e-05	CcSEcCtD
Citalopram—Headache—Capecitabine—breast cancer	1.03e-05	4.66e-05	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—breast cancer	1.03e-05	4.65e-05	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—breast cancer	1.02e-05	4.65e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—breast cancer	1.02e-05	4.63e-05	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—breast cancer	1.02e-05	4.62e-05	CcSEcCtD
Citalopram—Somnolence—Epirubicin—breast cancer	1.01e-05	4.6e-05	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—breast cancer	1.01e-05	4.57e-05	CcSEcCtD
Citalopram—Nausea—Docetaxel—breast cancer	1e-05	4.56e-05	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—breast cancer	1e-05	4.56e-05	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—breast cancer	1e-05	4.56e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Methotrexate—breast cancer	9.97e-06	4.53e-05	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—breast cancer	9.92e-06	4.5e-05	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—breast cancer	9.86e-06	4.48e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—breast cancer	9.85e-06	4.47e-05	CcSEcCtD
Citalopram—Fatigue—Epirubicin—breast cancer	9.84e-06	4.47e-05	CcSEcCtD
Citalopram—Constipation—Epirubicin—breast cancer	9.76e-06	4.43e-05	CcSEcCtD
Citalopram—Pain—Epirubicin—breast cancer	9.76e-06	4.43e-05	CcSEcCtD
Citalopram—Nausea—Capecitabine—breast cancer	9.73e-06	4.42e-05	CcSEcCtD
Citalopram—Urticaria—Methotrexate—breast cancer	9.68e-06	4.4e-05	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—breast cancer	9.64e-06	4.38e-05	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—breast cancer	9.64e-06	4.38e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—breast cancer	9.62e-06	4.37e-05	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—breast cancer	9.55e-06	4.33e-05	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—breast cancer	9.48e-06	4.3e-05	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—breast cancer	9.41e-06	4.27e-05	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—breast cancer	9.4e-06	4.27e-05	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—breast cancer	9.38e-06	4.26e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—breast cancer	9.33e-06	4.24e-05	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—breast cancer	9.29e-06	4.22e-05	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—breast cancer	9.18e-06	4.17e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—breast cancer	9.11e-06	4.14e-05	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—breast cancer	9.1e-06	4.13e-05	CcSEcCtD
Citalopram—Urticaria—Epirubicin—breast cancer	9.06e-06	4.11e-05	CcSEcCtD
Citalopram—Constipation—Doxorubicin—breast cancer	9.03e-06	4.1e-05	CcSEcCtD
Citalopram—Pain—Doxorubicin—breast cancer	9.03e-06	4.1e-05	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—breast cancer	9.02e-06	4.09e-05	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—breast cancer	9.02e-06	4.09e-05	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—breast cancer	8.98e-06	4.08e-05	CcSEcCtD
Citalopram—Asthenia—Methotrexate—breast cancer	8.75e-06	3.97e-05	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—breast cancer	8.7e-06	3.95e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—breast cancer	8.63e-06	3.92e-05	CcSEcCtD
Citalopram—Pruritus—Methotrexate—breast cancer	8.62e-06	3.92e-05	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—breast cancer	8.41e-06	3.82e-05	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—breast cancer	8.39e-06	3.81e-05	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—breast cancer	8.34e-06	3.79e-05	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—breast cancer	8.34e-06	3.79e-05	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—breast cancer	8.34e-06	3.79e-05	CcSEcCtD
Citalopram—Asthenia—Epirubicin—breast cancer	8.19e-06	3.72e-05	CcSEcCtD
Citalopram—Pruritus—Epirubicin—breast cancer	8.07e-06	3.66e-05	CcSEcCtD
Citalopram—Dizziness—Methotrexate—breast cancer	8.06e-06	3.66e-05	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—breast cancer	7.81e-06	3.54e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—breast cancer	7.78e-06	3.53e-05	CcSEcCtD
Citalopram—Vomiting—Methotrexate—breast cancer	7.75e-06	3.52e-05	CcSEcCtD
Citalopram—Rash—Methotrexate—breast cancer	7.69e-06	3.49e-05	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—breast cancer	7.68e-06	3.49e-05	CcSEcCtD
Citalopram—Headache—Methotrexate—breast cancer	7.64e-06	3.47e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—breast cancer	7.57e-06	3.44e-05	CcSEcCtD
Citalopram—Dizziness—Epirubicin—breast cancer	7.54e-06	3.42e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—breast cancer	7.47e-06	3.39e-05	CcSEcCtD
Citalopram—Vomiting—Epirubicin—breast cancer	7.25e-06	3.29e-05	CcSEcCtD
Citalopram—Nausea—Methotrexate—breast cancer	7.24e-06	3.29e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—breast cancer	7.22e-06	3.28e-05	CcSEcCtD
Citalopram—Rash—Epirubicin—breast cancer	7.19e-06	3.27e-05	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—breast cancer	7.19e-06	3.26e-05	CcSEcCtD
Citalopram—Headache—Epirubicin—breast cancer	7.15e-06	3.24e-05	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—breast cancer	6.98e-06	3.17e-05	CcSEcCtD
Citalopram—Nausea—Epirubicin—breast cancer	6.78e-06	3.08e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—breast cancer	6.71e-06	3.05e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—breast cancer	6.66e-06	3.02e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—breast cancer	6.65e-06	3.02e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—breast cancer	6.61e-06	3e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—breast cancer	6.27e-06	2.85e-05	CcSEcCtD
Citalopram—CYP1A2—Metabolism—GSTP1—breast cancer	2.24e-06	2.65e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—breast cancer	2.23e-06	2.65e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—breast cancer	2.23e-06	2.64e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—breast cancer	2.22e-06	2.64e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—breast cancer	2.21e-06	2.62e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HMOX1—breast cancer	2.2e-06	2.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SERPINE1—breast cancer	2.2e-06	2.62e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—breast cancer	2.2e-06	2.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ITPR1—breast cancer	2.2e-06	2.61e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	2.2e-06	2.61e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SERPINE1—breast cancer	2.2e-06	2.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	2.19e-06	2.6e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—breast cancer	2.18e-06	2.59e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—FASN—breast cancer	2.18e-06	2.58e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—breast cancer	2.17e-06	2.58e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—BCHE—breast cancer	2.17e-06	2.57e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	2.17e-06	2.57e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	2.16e-06	2.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—breast cancer	2.15e-06	2.56e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NOS3—breast cancer	2.15e-06	2.55e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAV1—breast cancer	2.15e-06	2.55e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—breast cancer	2.14e-06	2.54e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—breast cancer	2.14e-06	2.54e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—breast cancer	2.14e-06	2.54e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—breast cancer	2.14e-06	2.54e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—breast cancer	2.12e-06	2.51e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NOS3—breast cancer	2.11e-06	2.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOS3—breast cancer	2.1e-06	2.5e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—breast cancer	2.1e-06	2.5e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAV1—breast cancer	2.1e-06	2.49e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOS3—breast cancer	2.1e-06	2.49e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—breast cancer	2.08e-06	2.47e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—breast cancer	2.08e-06	2.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC2A1—breast cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NQO1—breast cancer	2.07e-06	2.46e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOS3—breast cancer	2.06e-06	2.45e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—breast cancer	2.06e-06	2.45e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—breast cancer	2.06e-06	2.44e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NCOR1—breast cancer	2.05e-06	2.44e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PLA2G4A—breast cancer	2.05e-06	2.44e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—breast cancer	2.05e-06	2.44e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.05e-06	2.44e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—breast cancer	2.05e-06	2.43e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—breast cancer	2.01e-06	2.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—breast cancer	2e-06	2.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—breast cancer	2e-06	2.38e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	2e-06	2.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—breast cancer	2e-06	2.37e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—breast cancer	1.99e-06	2.36e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RAF1—breast cancer	1.99e-06	2.36e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—breast cancer	1.99e-06	2.36e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—breast cancer	1.98e-06	2.36e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1B1—breast cancer	1.98e-06	2.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RAF1—breast cancer	1.98e-06	2.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RELA—breast cancer	1.98e-06	2.35e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAV1—breast cancer	1.98e-06	2.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RELA—breast cancer	1.97e-06	2.34e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—breast cancer	1.97e-06	2.34e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GPX1—breast cancer	1.97e-06	2.34e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—breast cancer	1.97e-06	2.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	1.97e-06	2.33e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—breast cancer	1.96e-06	2.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—breast cancer	1.96e-06	2.32e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—breast cancer	1.96e-06	2.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RAF1—breast cancer	1.95e-06	2.32e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—breast cancer	1.95e-06	2.31e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—breast cancer	1.95e-06	2.31e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—breast cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RELA—breast cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—breast cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—breast cancer	1.94e-06	2.31e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—breast cancer	1.94e-06	2.3e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—breast cancer	1.94e-06	2.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—breast cancer	1.94e-06	2.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—breast cancer	1.94e-06	2.3e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ERCC2—breast cancer	1.93e-06	2.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—breast cancer	1.93e-06	2.29e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—breast cancer	1.93e-06	2.29e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—breast cancer	1.91e-06	2.27e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	1.91e-06	2.26e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—breast cancer	1.91e-06	2.26e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK8—breast cancer	1.89e-06	2.25e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOA1—breast cancer	1.89e-06	2.25e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—breast cancer	1.89e-06	2.24e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—breast cancer	1.87e-06	2.22e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—STK11—breast cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP19A1—breast cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—breast cancer	1.86e-06	2.21e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—breast cancer	1.85e-06	2.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—breast cancer	1.85e-06	2.19e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—breast cancer	1.83e-06	2.17e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—breast cancer	1.82e-06	2.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—breast cancer	1.82e-06	2.16e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—breast cancer	1.82e-06	2.16e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—breast cancer	1.82e-06	2.16e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—breast cancer	1.8e-06	2.14e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—breast cancer	1.8e-06	2.14e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—breast cancer	1.8e-06	2.13e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—breast cancer	1.8e-06	2.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	1.79e-06	2.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—breast cancer	1.79e-06	2.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—breast cancer	1.78e-06	2.12e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—breast cancer	1.78e-06	2.11e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—breast cancer	1.78e-06	2.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—breast cancer	1.77e-06	2.11e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	1.77e-06	2.1e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—breast cancer	1.77e-06	2.1e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—breast cancer	1.75e-06	2.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—breast cancer	1.75e-06	2.08e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—breast cancer	1.75e-06	2.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—breast cancer	1.74e-06	2.07e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—breast cancer	1.74e-06	2.06e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—breast cancer	1.73e-06	2.06e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—COMT—breast cancer	1.73e-06	2.06e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—breast cancer	1.73e-06	2.06e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—breast cancer	1.73e-06	2.06e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—breast cancer	1.73e-06	2.05e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—breast cancer	1.73e-06	2.05e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—breast cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—breast cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—breast cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—breast cancer	1.72e-06	2.04e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—breast cancer	1.71e-06	2.03e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—breast cancer	1.7e-06	2.02e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HMOX1—breast cancer	1.7e-06	2.02e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—breast cancer	1.7e-06	2.02e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ITPR1—breast cancer	1.7e-06	2.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	1.69e-06	2.01e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—breast cancer	1.69e-06	2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—breast cancer	1.68e-06	2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—breast cancer	1.68e-06	2e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—breast cancer	1.68e-06	1.99e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—breast cancer	1.68e-06	1.99e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—breast cancer	1.68e-06	1.99e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—breast cancer	1.68e-06	1.99e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAV1—breast cancer	1.67e-06	1.99e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—breast cancer	1.67e-06	1.99e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—breast cancer	1.66e-06	1.97e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—breast cancer	1.66e-06	1.97e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—breast cancer	1.65e-06	1.96e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	1.65e-06	1.96e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.65e-06	1.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK8—breast cancer	1.64e-06	1.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—breast cancer	1.64e-06	1.94e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK8—breast cancer	1.64e-06	1.94e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—breast cancer	1.63e-06	1.94e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—breast cancer	1.63e-06	1.94e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NOS3—breast cancer	1.62e-06	1.93e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.61e-06	1.91e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—breast cancer	1.61e-06	1.91e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.61e-06	1.91e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—breast cancer	1.61e-06	1.91e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—breast cancer	1.6e-06	1.9e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.6e-06	1.9e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NOS3—breast cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOR1—breast cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—breast cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.59e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—breast cancer	1.58e-06	1.88e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—breast cancer	1.57e-06	1.87e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—breast cancer	1.56e-06	1.85e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—breast cancer	1.56e-06	1.85e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—breast cancer	1.55e-06	1.84e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—breast cancer	1.53e-06	1.81e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—breast cancer	1.53e-06	1.81e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GPX1—breast cancer	1.52e-06	1.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—breast cancer	1.52e-06	1.8e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—breast cancer	1.51e-06	1.79e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—breast cancer	1.5e-06	1.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—breast cancer	1.5e-06	1.78e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—breast cancer	1.5e-06	1.78e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—breast cancer	1.5e-06	1.78e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NOS3—breast cancer	1.49e-06	1.77e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ERCC2—breast cancer	1.49e-06	1.77e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.49e-06	1.77e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—breast cancer	1.49e-06	1.77e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—breast cancer	1.49e-06	1.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.47e-06	1.75e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—breast cancer	1.46e-06	1.74e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—breast cancer	1.45e-06	1.72e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—breast cancer	1.43e-06	1.7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—breast cancer	1.43e-06	1.7e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.41e-06	1.67e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—breast cancer	1.4e-06	1.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—breast cancer	1.39e-06	1.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—breast cancer	1.39e-06	1.65e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—breast cancer	1.39e-06	1.65e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—breast cancer	1.39e-06	1.65e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—breast cancer	1.38e-06	1.64e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—breast cancer	1.37e-06	1.62e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—breast cancer	1.37e-06	1.62e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.37e-06	1.62e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.36e-06	1.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—breast cancer	1.36e-06	1.62e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—breast cancer	1.36e-06	1.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—breast cancer	1.34e-06	1.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.34e-06	1.59e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—breast cancer	1.32e-06	1.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—breast cancer	1.32e-06	1.57e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—breast cancer	1.3e-06	1.54e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAV1—breast cancer	1.29e-06	1.53e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—breast cancer	1.29e-06	1.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—breast cancer	1.28e-06	1.52e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NOS3—breast cancer	1.27e-06	1.5e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—breast cancer	1.27e-06	1.5e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.26e-06	1.5e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—breast cancer	1.26e-06	1.5e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—breast cancer	1.21e-06	1.44e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—breast cancer	1.21e-06	1.44e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—breast cancer	1.19e-06	1.42e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—breast cancer	1.19e-06	1.41e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—breast cancer	1.18e-06	1.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.18e-06	1.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—breast cancer	1.18e-06	1.4e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—breast cancer	1.17e-06	1.39e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.16e-06	1.38e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—breast cancer	1.16e-06	1.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—breast cancer	1.15e-06	1.36e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—breast cancer	1.14e-06	1.36e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—breast cancer	1.12e-06	1.33e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—breast cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—breast cancer	1.1e-06	1.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—breast cancer	1.09e-06	1.3e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.07e-06	1.28e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—breast cancer	1.05e-06	1.24e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—breast cancer	1.04e-06	1.24e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—breast cancer	1.03e-06	1.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—breast cancer	1.03e-06	1.22e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—breast cancer	1.02e-06	1.21e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—breast cancer	1.01e-06	1.2e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—breast cancer	9.88e-07	1.17e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NOS3—breast cancer	9.77e-07	1.16e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—breast cancer	9.68e-07	1.15e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—breast cancer	9.67e-07	1.15e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—breast cancer	9.64e-07	1.14e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—breast cancer	9.49e-07	1.13e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—breast cancer	9.14e-07	1.09e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—breast cancer	9.02e-07	1.07e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—breast cancer	8.94e-07	1.06e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—breast cancer	8.92e-07	1.06e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—breast cancer	8.41e-07	9.98e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—breast cancer	7.79e-07	9.25e-06	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—breast cancer	7.47e-07	8.87e-06	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—breast cancer	7.29e-07	8.66e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—breast cancer	7.12e-07	8.46e-06	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—breast cancer	6.87e-07	8.16e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—breast cancer	5.82e-07	6.91e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—breast cancer	5.5e-07	6.53e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—breast cancer	4.49e-07	5.33e-06	CbGpPWpGaD
